High Glucose and Lipopolysaccharide Prime NLRP3 Inflammasome via ROS/TXNIP Pathway in Mesangial Cells

Journal of Diabetes Research

Volumn 2016, Issue , 2016, Pages

  Feng, Hong ^a,b   Gu, Junling ^c   Gou, Fang ^a   Huang, Wei ^a   Gao, Chenlin ^a   Chen, Guo ^a   Long, Yang ^a   Zhou, Xueqin ^a   Yang, Maojun ^a   Liu, Shuang ^a   Lü, Shishi ^a   Luo, Qiaoyan ^a   Xu, Yong ^a  

^a SOUTHWEST MEDICAL UNIVERSITY   (China)

^b Nan'An District People's Hospital   (China)

^c The Fifth People's Hospital of Chongqing   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CASPASE; CRYOPYRIN; GLUCOSE; INFLAMMASOME; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MESSENGER RNA; PROCASPASE 1; PROTEIN; PROTEIN PRECURSOR; REACTIVE OXYGEN METABOLITE; THIOREDOXIN INTERACTING PROTEIN; UNCLASSIFIED DRUG; CARRIER PROTEIN; GLUCOSE BLOOD LEVEL; INTERLEUKIN 1BETA CONVERTING ENZYME; NLRP3 PROTEIN, RAT; TXNIP PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MALE; MESANGIUM CELL; MOLECULAR PATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; ANALYSIS; ANIMAL; BLOOD; GLUCOSE BLOOD LEVEL; METABOLISM; RANDOMIZATION;

ACETYLCYSTEINE; ANIMALS; BLOOD GLUCOSE; CARRIER PROTEINS; CASPASE 1; GLUCOSE; IMMUNOHISTOCHEMISTRY; INFLAMMASOMES; INFLAMMATION; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; MALE; MESANGIAL CELLS; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; RANDOM ALLOCATION; RATS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 84955620567     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2016/6973175     Document Type: Article

References (50)

1. C.-C. Wu, J.-S. Chen, K.-C. Lu et al., "Aberrant cytokines/chemokines production correlate with proteinuria in patients with overt diabetic nephropathy, " Clinica Chimica Acta, vol. 411, no. 9-10, pp. 700-704, 2010.
2. J. Wada and H. Makino, "Inflammation and the pathogenesis of diabetic nephropathy, " Clinical Science, vol. 124, no. 3, pp. 139-152, 2013.
3. J. M. Ferńandez-Real and J. C. Pickup, "Innate immunity, insulin resistance and type 2 diabetes, " Diabetologia, vol. 55, no. 2, pp. 273-278, 2012.
4. T. Kawai and S. Akira, "The roles of TLRs, RLRs and NLRs in pathogen recognition, " International Immunology, vol. 21, no. 4, pp. 317-337, 2009.
5. M. A. Mori, O. Bezy, and C. R. Kahn, "Metabolic syndrome: is Nlrp3 inflammasome a trigger or a target of insulin resistance?" Circulation Research, vol. 108, no. 10, pp. 1160-1162, 2011.
6. Y.-H. Youm, A. Adijiang, B. Vandanmagsar, D. Burk, A. Ravussin, and V. D. Dixit, "Elimination of the NLRP3-ASC inflammasome protects against chronic obesity-induced pancreatic damage, " Endocrinology, vol. 152, no. 11, pp. 4039-4045, 2011.
7. M. Ganz, T. Csak, and G. Szabo, "High fat diet feeding results in gender specific steatohepatitis and inflammasome activation, " World Journal of Gastroenterology, vol. 20, no. 26, pp. 8525-8534, 2014.
8. P. D. Cani, M. Osto, L. Geurts, and A. Everard, "Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity, " Gut Microbes, vol. 3, no. 4, pp. 279-288, 2012.
9. M. K. Piya, A. L. Harte, and P. G. McTernan, "Metabolic endotoxaemia: is it more than just a gut feeling?" Current Opinion in Lipidology, vol. 24, no. 1, pp. 78-85, 2013.
10. L. Perrone, T. S. Devi, K.-I. Hosoya, T. Terasaki, and L. P. Singh, "Thioredoxin interacting protein (TXNIP) induces inflammation through chromatin modification in retinal capillary endothelial cells under diabetic conditions, " Journal of Cellular Physiology, vol. 221, no. 1, pp. 262-272, 2009.
11. J. Chen, G. Saxena, I. N. Mungrue, A. J. Lusis, and A. Shalev, "Thioredoxin-interacting protein: A critical link between glucose toxicity and-cell apoptosis, " Diabetes, vol. 57, no. 4, pp. 938-944, 2008.
12. D.W. Cheng, Y. Jiang, A. Shalev, R. Kowluru, E. D. Crook, andL. P. Singh, "An analysis of high glucose and glucosamine-induced gene expression and oxidative stress in renal mesangial cells, " Archives of Physiology and Biochemistry, vol. 112, no. 4-5, pp. 189-218, 2006.
13. P. C. Schulze, J. Yoshioka, T. Takahashi, Z. He, G. L. King, and R. T. Lee, "Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein, " Journal of Biological Chemistry, vol. 279, no. 29, pp. 30369-30374, 2004.
14. M. T. Forrester, D. Seth, A. Hausladen et al., "Thioredoxininteracting protein (Txnip) is a feedback regulator of Snitrosylation, " Journal of Biological Chemistry, vol. 284, no. 52, pp. 36160-36166, 2009.
15. R. Zhou, A. Tardivel, B. Thorens, I. Choi, and J. Tschopp, "Thioredoxin-interacting protein links oxidative stress to inflammasome activation, " Nature Immunology, vol. 11, no. 2, pp. 136-140, 2010.
16. K. Schroder, R. Zhou, and J. Tschopp, "The NLRP3 inflammasome: A sensor formetabolic danger?" Science, vol. 327, no. 5963, pp. 296-300, 2010.
17. G. B. Nogueira, A. M. Rodrigues, F. R. Maciel et al., "Nacetylcysteine and oxidative stress in the kidney of uninephrectomized rats with diabetes mellitus, " in Proceedings of the Annual Meeting on ASN Kidney Week, vol. 1, Philadelphia, Pa, USA, 2011.
18. E. P. Da Silva Jr. and R. H. Lambertucci, "Effects of N-Acetylcysteine and L-Arginine in the antioxidant system of C2C12 cells, " The Journal of Sports Medicine and Physical Fitness, vol. 55, no. 6, pp. 691-699, 2015.
19. C. K. Sen, "Antioxidant and redox regulation of cellular signaling: introduction, " Medicine and Science in Sports and Exercise, vol. 33, no. 3, pp. 368-370, 2001.
20. P. Gao, X. F. Meng, H. Su et al., "Thioredoxin-interacting protein mediates NALP3 inflammasome activation in podocytes duringdiabetic nephropathy, " Biochim Biophys Acta, vol. 1843, no. 11, pp. 2448-2460, 2014.
21. B. Luo, B. Li, W. Wang et al., "NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model, " PLoS ONE, vol. 9, no. 8, Article ID e104771, 2014.
22. H.Y. Chen, X. R. Huang, W. Wang et al., "The protective role of Smad7 in diabetic kidney disease: mechanism and therapeutic potential, " Diabetes, vol. 60, no. 2, pp. 590-601, 2011.
23. E. ͆anchez-Ĺopez, J. Rodriguez-Vita, C. Cartier et al., "Inhibitory effect of interleukin-1 beta on angiotensin IIinduced connective tissue growth factor and type IV collagen production in cultured mesangial cells, " The American Journal of Physiology-Renal Physiology, vol. 294, no. 1, pp. F149-F160, 2008.
24. K. Chen, J. Zhang, W. Zhang et al., "ATP-P2X4 signaling mediates NLRP3 inflammasome activation: A novel pathway of diabetic nephropathy, "The International Journal of Biochemistry &Cell Biology, vol. 45, no. 5, pp. 932-943, 2013.
25. S. Maeda, "Do inflammatory cytokine genes confer susceptibility to diabetic nephropathy?" Kidney International, vol. 74, no. 4, pp. 413-415, 2008.
26. R. W. Grant and V. D. Dixit, "Mechanisms of disease: inflammasome activation and the development of type 2 diabetes, " Frontiers in Immunology, vol. 4, no. 4, article 50, 2013.
27. A. Babelova, K. Moreth, W. Tsalastra-Greul et al., "Biglycan, a danger signal that activates the NLRP3 inflammasome via tolllike and P2X receptors, "The Journal of Biological Chemistry, vol. 284, no. 36, pp. 24035-24048, 2009.
28. T. Jourdan, G. Godlewski, R. Cinar et al., "Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates cell loss in type 2 diabetes, " Nature Medicine, vol. 19, no. 9, pp. 1132-1140, 2013.
29. S. Sun, S. Xia, Y. Ji, S. Kersten, and L. Qi, "The ATP-P2X 7 signaling axis is dispensable for obesity-Associated inflammasome activation in adipose tissue, " Diabetes, vol. 61, no. 6, pp. 1471-1478, 2012.
30. Y. Yin, J. L. Pastrana, X. Li et al., "Inflammasomes: sensors of metabolic stresses for vascular inflammation, " Frontiers in Bioscience, vol. 18, no. 8, pp. 638-649, 2013.
31. M. S. Lee, "Role of innateimmunity in diabetes andmetabolism: recent progress in the study of inflammasomes, " Immune Network, vol. 11, no. 2, pp. 95-99, 2011.
32. C. Wang, Y. Pan, Q.-Y. Zhang, F.-M. Wang, and L.-D. Kong, "Quercetin and allopurinol ameliorate kidney injury in STZtreated rats with regulation of renal NLRP3 inflammasome activation and lipid accumulation, " PLoS ONE, vol. 7, no. 6, Article ID e38285, 2012.
33. E. Benetti, F. Chiazza, N. S. A. Patel, and M. Collino, "The NLRP3 inflammasome as a novel player of the intercellular crosstalk in metabolic disorders, " Mediators of Inflammation, vol. 2013, Article ID 678627, 9 pages, 2013.
34. P. Duewell, H. Kono, K. J. Rayner et al., "NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals, " Nature, vol. 464, no. 7293, pp. 1357-1361, 2010.
35. P. J. Pussinen, A. S. Havulinna, M. Lehto, J. Sundvall, and V. Salomaa, "Endotoxemia is associated with an increased risk of incident diabetes, " Diabetes Care, vol. 34, no. 2, pp. 392-397, 2011.
36. M. I. Lassenius, K. H. Pietiläinen, K. Kaartinen et al., "Bacterial endotoxin activity in human serum is associated with dyslipidemia, insulin resistance, obesity, and chronic inflammation, " Diabetes Care, vol. 34, no. 8, pp. 1809-1815, 2011.
37. M. Nymark, P. J. Pussinen, A. M. Tuomainen, C. Forsblom, P.-H. Groop, and M. Lehto, "Serum lipopolysaccharide activity is associated with the progression of kidney disease in finnish patients with type 1 diabetes, " Diabetes Care, vol. 32, no. 9, pp. 1689-1693, 2009.
38. A. B. Hauser, A. E. M. Stinghen, S.M. Gonçalves, S. Bucharles, and R. Pecoits-Filho, "A gut feeling on endotoxemia: causes and consequences in chronic kidney disease, " Nephron Clinical Practice, vol. 118, no. 2, pp. 165-172, 2011.
39. M. Manco, L. Putignani, and G. F. Bottazzo, "Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk, " Endocrine Reviews, vol. 31, no. 6, pp. 817-844, 2010.
40. T. S. Devi, I. Lee, M. Hüttemann, A. Kumar, K. D. Nantwi, and L. P. Singh, "TXNIP links innate host defense mechanisms to oxidative stress and inflammation in retinal muller glia under chronic hyperglycemia: implications for diabetic retinopathy, " Experimental Diabetes Research, vol. 2012, Article ID438238, 19 pages, 2012.
41. S. M. Tan, Y. Zhang, A. J. Cox, D. J. Kelly, andW. Qi, "Tranilast attenuates the up-regulation of thioredoxin-interacting protein and oxidative stress in an experimental model of diabetic nephropathy, " Nephrology Dialysis Transplantation, vol. 26, no. 1, pp. 100-110, 2011.
42. A. Advani, R. E. Gilhert, K. Thai et al., "Expression, localization, and function of the thioredoxin system in diabetic nephropathy, " Journal of the American Society of Nephrology, vol. 20, no. 4, pp. 730-741, 2009.
43. W. Huang, C. Yang, Q. Nan et al., "The proteasome inhibitor, MG132, attenuates diabetic nephropathy by inhibiting SnoN degradation in vivo and in vitro, " BioMed Research International, vol. 2014, Article ID 684765, 11 pages, 2014.
44. R. Stienstra, C. J. Tack, T.-D. Kanneganti, L. A. B. Joosten, and M. G. Netea, "The inflammasome puts obesity in the danger zone, " Cell Metabolism, vol. 15, no. 1, pp. 10-18, 2012.
45. R. Z. Alicic andK. R. Tuttle, "Novel therapies for diabetic kidney disease, " Advances in Chronic Kidney Disease, vol. 21, no. 2, pp. 121-133, 2014.
46. P. Fiorina, A. Vergani, R. Bassi et al., "Role of podocyte B7-1 in diabetic nephropathy, " Journal of the American Society of Nephrology, vol. 25, no. 7, pp. 1415-1429, 2014.
47. A. Doria, M. A. Niewczas, and P. Fiorina, "Can existing drugs approved for other indications retard renal function decline in patients with type 1 diabetes and nephropathy?" Seminars in Nephrology, vol. 32, no. 5, pp. 437-444, 2012.
48. A. M. Rodrigues, C. T. Bergamaschi, M. J. S. Fernandes et al., "P2x7 receptor in the kidneys of diabetic rats submitted to aerobic training or to N-Acetylcysteine supplementation, " PLoS ONE, vol. 9, no. 6, Article ID e97452, 2014.
49. A. Solini, V. Usuelli, and P. Fiorina, "The dark side of extracellular ATP in kidney diseases, " Journal of the American Society of Nephrology, vol. 26, no. 5, pp. 1007-1016, 2015.
50. M. G. Saklayen, J. Yap, and V. Vallyathan, "Effect ofmonth-long treatment with oral N-Acetylcysteine on the oxidative stress and proteinuria in patientswith diabetic nephropathy: A pilot study, " Journal of Investigative Medicine, vol. 58, no. 1, pp. 28-31, 2010.